A Post Marketing Surveillance on Lutathera® in Patients With Somatostatin Receptor Positive Gastroenteropancreatic Neuroendocrine Tumor in Korea
A Post Marketing Surveillance on Lutathera® (Lutetium (177Lu) Oxodotreotide, 177Lu-DOTA0-Tyr3-Octreotate) in Patients With Somatostatin Receptor Positive Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) in Korea
Sponsor: Novartis Pharmaceuticals
A observational or N/A phase clinical study on Somatostatin Receptor-positive GEP-NET, this trial is completed. The trial is conducted by Novartis Pharmaceuticals and has accumulated 10 data snapshots since 2022. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Completed
-
Sep 2024 — Sep 2025 [monthly]
Completed
Status: Active Not Recruiting → Completed
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting
-
May 2024 — Jul 2024 [monthly]
Active Not Recruiting
Status: Recruiting → Active Not Recruiting
-
Oct 2023 — May 2024 [monthly]
Recruiting
▶ Show 5 earlier versions
-
Sep 2022 — Oct 2023 [monthly]
Recruiting
-
Jul 2022 — Sep 2022 [monthly]
Recruiting
Status: Not Yet Recruiting → Recruiting
-
Mar 2022 — Jul 2022 [monthly]
Not Yet Recruiting
-
Feb 2022 — Mar 2022 [monthly]
Not Yet Recruiting
-
Sep 2021 — Feb 2022 [monthly]
Not Yet Recruiting
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Novartis Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .